This conversation starts with Quentin Anstee complimenting Stephen Harrison for his observation that when we analyze NASH Biomarkers, we should consider the value of sustained response separate from early OR late response.

From here, the group moves to the concept of “stacked” tests — confirmatory results from different NITs as a way to assess efficacy in an individual clinical trial subject. The conversation takes some twists and turns, but the core concept is unique, challenging and a significant step forward in the broader discussion of how to analyze biomarkers.